Wearable diagnostics are poised to transform subjective, episodic measures of disease progression to quantified, continuous data streams, according to some industry experts.
18 in after-market trading. Shares of Incyte have risen 5.4% year to date against the industry’s 11.1% decline. Incyte announced that it will pause enrollment in the ongoing phase II study of MRGPRX2 ...